Eric Lu1, Kathryn E Hatchell2, Sarah M Nielsen2, Edward D Esplin2, Karen Ouyang2, Keith Nykamp2, Shirin Zavoshi3, Shantao Li4, Liying Zhang5,6, Blake R Wilde7, Heather R Christofk6,7, Paul C Boutros3,6,8,9, Brian Shuch3,6. 1. Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California. 2. Invitae, San Francisco, California. 3. Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, California. 4. Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut. 5. Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California. 6. Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California. 7. Department of Biological Chemistry, University of California Los Angeles, Los Angeles, California. 8. Department of Human Genetics, University of California Los Angeles, Los Angeles, California. 9. Department of Urology, University of California Los Angeles, Los Angeles, California.
Abstract
BACKGROUND: Germline variants in fumarate hydratase (FH) are associated with autosomal dominant (AD) hereditary leiomyomatosis and renal cell cancer (HLRCC) and autosomal recessive (AR) fumarase deficiency (FMRD). The prevalence and cancer penetrance across different FH variants remain unclear. METHODS: A database containing 120,061 records from individuals undergoing cancer germline testing was obtained. FH variants were classified into 3 categories: AD HLRCC variants, AR FMRD variants, and variants of unknown significance (VUSs). Individuals with variants from these categories were compared with those with negative genetic testing. RESULTS: FH variants were detected in 1.3% of individuals (AD HLRCC, 0.3%; AR FMRD, 0.4%; VUS, 0.6%). The rate of AD HLRCC variants discovered among reportedly asymptomatic individuals without a clear indication for HLRCC testing was 1 in 2668 (0.04%). In comparison with those with negative genetic testing, the renal cell carcinoma (RCC) prevalence was elevated with AD HLRCC variants (17.0% vs 4.5%; P < .01) and VUSs (6.4% vs 4.5%; P = .02) but not with AR FMRD variants. CONCLUSIONS: The prevalence of HLRCC discovered incidentally on germline testing is similar to recent population carrier estimates, and this suggests that this is a relatively common cancer syndrome. Compared with those with negative genetic testing, those with VUSs had an elevated risk of RCC, whereas those with AR FMRD variants did not.
BACKGROUND: Germline variants in fumarate hydratase (FH) are associated with autosomal dominant (AD) hereditary leiomyomatosis and renal cell cancer (HLRCC) and autosomal recessive (AR) fumarase deficiency (FMRD). The prevalence and cancer penetrance across different FH variants remain unclear. METHODS: A database containing 120,061 records from individuals undergoing cancer germline testing was obtained. FH variants were classified into 3 categories: AD HLRCC variants, AR FMRD variants, and variants of unknown significance (VUSs). Individuals with variants from these categories were compared with those with negative genetic testing. RESULTS: FH variants were detected in 1.3% of individuals (AD HLRCC, 0.3%; AR FMRD, 0.4%; VUS, 0.6%). The rate of AD HLRCC variants discovered among reportedly asymptomatic individuals without a clear indication for HLRCC testing was 1 in 2668 (0.04%). In comparison with those with negative genetic testing, the renal cell carcinoma (RCC) prevalence was elevated with AD HLRCC variants (17.0% vs 4.5%; P < .01) and VUSs (6.4% vs 4.5%; P = .02) but not with AR FMRD variants. CONCLUSIONS: The prevalence of HLRCC discovered incidentally on germline testing is similar to recent population carrier estimates, and this suggests that this is a relatively common cancer syndrome. Compared with those with negative genetic testing, those with VUSs had an elevated risk of RCC, whereas those with AR FMRD variants did not.
Authors: V Launonen; O Vierimaa; M Kiuru; J Isola; S Roth; E Pukkala; P Sistonen; R Herva; L A Aaltonen Journal: Proc Natl Acad Sci U S A Date: 2001-02-27 Impact factor: 11.205
Authors: N Kuroda; M Furuya; Y Nagashima; H Gotohda; F Kawakami; S Moritani; S Ota; M Hora; M Michal; O Hes; Y Nakatani Journal: Pol J Pathol Date: 2014-06 Impact factor: 1.072
Authors: Claire Forde; Derek H K Lim; Yousef Alwan; George Burghel; Laura Butland; Ruth Cleaver; Abhijit Dixit; D Gareth Evans; Helen Hanson; Fiona Lalloo; Pedro Oliveira; Lindsey Vialard; Yvonne Wallis; Eamonn R Maher; Emma R Woodward Journal: Eur Urol Oncol Date: 2019-12-09
Authors: Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz Journal: Cancer Discov Date: 2012-05 Impact factor: 39.397
Authors: Brian Shuch; Shantao Li; Harvey Risch; Ranjit S Bindra; Patrick D McGillivray; Mark Gerstein Journal: Cancer Date: 2020-05-15 Impact factor: 6.860